vimarsana.com
Home
Live Updates
CARsgens CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection : comparemela.com
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection
SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for
Related Keywords
Thailand ,
Shanghai ,
China ,
Raffaele Baffa ,
National Medical Products Administration ,
Carsgen Therapeutics Holdings Limited Stock Code ,
Carsgen Therapeutics Holdings ,
Therapeutics Holdings Limited ,
Stock Code ,
Investigational New Drug ,
Chief Medical Officer ,
Therapeutics Holdings ,
Thailand Business ,
comparemela.com © 2020. All Rights Reserved.